DePARylation is critical for S phase progression and cell survival
eLife · 05.04.2024 · 12
DOI: 10.7554/elife.89303 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 05.04.2024. Verfasst von Litong Nie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Hauptthemen laut MEDLINE: Poly Adenosine Diphosphate Ribose, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Cancer Institute.
Abstract (Originalsprache)
Poly(ADP-ribose)ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation by poly(ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic regulation of DNA damage response. PARG, the most active dePARylation enzyme, is recruited to sites of DNA damage via pADPr-dependent and PCNA-dependent mechanisms. Targeting dePARylation is considered an alternative strategy to overcome PARP inhibitor resistance. However, precisely how dePARylation functions in normal unperturbed cells remains elusive. To address this challenge, we conducted multiple CRISPR screens and revealed that dePARylation of S phase pADPr by PARG is essential for cell viability. Loss of dePARylation activity initially induced S-phase-specific pADPr signaling, which resulted from unligated Okazaki fragments and eventually led to uncontrolled pADPr accumulation and PARP1/2-dependent cytotoxicity. Moreover, we demonstrated that proteins involved in Okazaki fragment ligation and/or base excision repair regulate pADPr signaling and cell death induced by PARG inhibition. In addition, we determined that PARG expression is critical for cellular sensitivity to PARG inhibition. Additionally, we revealed that PARG is essential for cell survival by suppressing pADPr. Collectively, our data not only identify an essential role for PARG in normal proliferating cells but also provide a potential biomarker for the further development of PARG inhibitors in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
- Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, United States.
ORCID-Profile: Litong Nie, Li Ma, Junjie Chen
Förderung
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
Zitieren
APA
Nie, L., Wang, C., Huang, M., Liu, X., Feng, X., Tang, M., Li, S., Hang, Q., Teng, H., Shen, X., Ma, L., Gan, B., & Chen, J. (2024). DePARylation is critical for S phase progression and cell survival. eLife, 12. https://doi.org/10.7554/elife.89303
Vancouver
Nie L, Wang C, Huang M, Liu X, Feng X, Tang M, et al. DePARylation is critical for S phase progression and cell survival. eLife. 2024;12. doi:10.7554/elife.89303
BibTeX
@article{Nie2024,
author = {Nie, Litong and Wang, Chao and Huang, Min and Liu, Xiaoguang and Feng, Xu and Tang, Mengfan and Li, Siting and Hang, Qinglei and Teng, Hongqi and Shen, Xi and Ma, Li and Gan, Boyi and Chen, Junjie},
title = {DePARylation is critical for S phase progression and cell survival},
journal = {eLife},
year = {2024},
volume = {12},
doi = {10.7554/elife.89303}
}
EUVIMED